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Abstract
Chronic myeloid leukemia (CML) in children and young adults is uncommon. Young patients 
have long life expectancies and low morbidity with hematopoietic cell transplantation (HCT). 
Prolonged tyrosine kinase inhibitor (TKI) use may cause significant morbidity. In addition 
indication for HCT in patients in first chronic phase is not established.
We hence retrospectively evaluated outcomes in 449 CML patients with early disease receiving 
myeloablative HCT reported to the CIBMTR. We analyzed various factors affecting outcome 
specifically the effect of age and pre-HCT TKI in pediatric patients (<18 yrs, n= 177) and young 
adults (18–29 years, n=272) with the goal of identifying prognostic factors.
Post-HCT probability of 5 y overall survival (OS) and leukemia free survival (LFS) were 75% and 
59% respectively. OS and LFS were 76%, 57% in <18 yr and 74%, 60% in 18–29 yr group 
respectively by univariate analysis (p= 0.1 and 0.6). Five-year OS for human leukocyte antigen 
(HLA) matched sibling donor (MSD) and bone marrow (BM) stem cell source were 83% and 80% 
respectively. In multivariate analysis, there was no effect of age (<18 vs 18–29) or pre-HCT TKI 
therapy on OS, LFS, transplant related mortality (TRM) or relapse. Favorable factors for OS were 
MSD (p<0.001) and recent HCT (2003–2010) (p=0.04). LFS was superior with MSD (P<0.001), 
BM as graft source (P=0.001) and performance score >90 (P=0.03) compared to unrelated or 
mismatched, peripheral blood stem cells donors and recipients with lower performance scores. 
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Older age was associated with increased incidence of chronic graft vs. host disease (cGVHD) 
(p=0.0002).
In the current era, HCT outcomes are similar in young patients and children with early CML, and 




Chronic myeloid leukemia (CML) in pediatrics and young adults is uncommon accounting 
for only about 3% of all leukemias and <10% of all reported CML.1 Since the introduction 
of tyrosine kinase inhibitors (TKI) (e.g. imatinib, dasatinib, nilotinib etc.), hematopoietic 
cell transplantation (HCT) in patients with CML, especially among those with early disease, 
has declined.2,3 HCT is usually only offered to selected patients with inadequate response or 
intolerance to TKI, and it is generally recommended to continue TKI indefinitely without 
HCT.3,4,5 Indications for HCT in children and young adults are extrapolated from adult 
studies and include advanced disease, presence of resistant mutation or failure to achieve 
complete cytological remission 1 year after initiation of TKI therapy. 6,7,8 Children and 
young adults with projected longer life expectancies are likely to receive prolonged TKI 
therapy during periods of active growth and sexual development, which may increase 
cumulative risk for known and yet unknown morbidities.9,10,11,12 Given that results of HCT 
are superior in children and younger adults compared to older adults, it may be assumed that 
HCT for chronic phase (CP) is beneficial by curing disease at lower cost, without need for 
prolonged TKIs, especially if an appropriate donor is available.12,13 We conducted a 
retrospective cohort study of patients 0–29 years of age with early CML (defined as first 
chronic phase (CP1) and clinical remission as captured in CBMTR forms) who received a 
myeloablative conditioning (MAC) allogeneic HCT. We reviewed outcomes of children <18 




The CIBMTR (Center for International Blood and Marrow Transplant Research) is a 
research collaboration between the National Marrow Donor Program/Be The Match and the 
Medical College of Wisconsin. It comprises a voluntary working group of more than 450 
transplantation centers worldwide that contribute detailed data on consecutive allogeneic and 
autologous hematopoietic cell transplantation. Participating centers are required to report all 
transplants consecutively; compliance is monitored by on-site audits and patients are 
followed longitudinally. Computerized checks for discrepancies, physicians’ review of 
submitted data, and on site audits of participating centers ensure data quality. Studies 
conducted by the CIBMTR are performed in compliance with all applicable federal 
regulations pertaining to the protection of human research participants. Protected Health 
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Information used in the performance of such research is collected and maintained in 
CIBMTR’s capacity as a Public Health Authority under the Health Insurance Portability and 
Accountability Act Privacy Rule.
The CIBMTR collects data at two levels: Transplant Essential Data (TED) level and 
Comprehensive Report Form (CRF) level. The TED-level data is an international accepted 
standard data set that contains a limited number of key variables for all consecutive 
transplant recipients. TED-level data, with some additional details of donor and graft 
characteristics, comprise the obligatory data submitted to the SCTOD (Stem Cell 
Therapeutic Outcomes Database). When a transplant is registered with the CIBMTR; a 
subset of patients are selected for CRF-level data through a weighted randomization scheme. 
The CRF-level captures additional patient, disease and treatment-related data. TED and CRF 
level data are collected pre-transplant, 100 days and six months post HCT, annually until 
year 6 post-transplant and biannually thereafter until death. Data for these analyses were 
retrieved from CIBMTR (TED and CRF) report forms.
Patient selection
We identified 2785 patients with CML who received allogeneic HCT between 2001 and 
2010. We excluded from the analysis patients with age >29 years (n=1964); advanced and 
intermediate disease defined as accelerated phase, blast crisis and second chronic phase or 
greater (n=197); non-myeloablative or reduced intensity conditioning regimen (n=56); cord 
blood graft (n= 39); In vitro T cell depletion/CD34 selection (n= 36); lack of HLA matching 
data (n=27); additional missing data (n=16); and one patient who died on stem cell infusion 
day. Exclusion was due to either incomplete data or different projected course and outcomes 
based on different conditioning regimens and sources. The final study population consisted 
of a total of 449 patients 0–29 years that received myeloablative conditioning regimen in 
early CML.
Study definitions
Primary outcomes were overall survival (OS) and leukemia-free survival (LFS). For OS, 
patients were considered to have an event at the time of death from any cause. LFS was 
defined as time to the first of either relapse or death from any cause. For OS and LFS, 
patients alive in continuous complete remission were censored at last follow-up. Relapse 
was defined by submitting centers and included hematologic, molecular and cytogenetic 
relapse. Secondary outcomes included hematopoietic recovery as defined by time to 
neutrophils (ANC) >0.5 × 109/L (first of 3 consecutive days) and time to platelets ≥20 × 
109/L (first of 3 consecutive days and no platelet transfusions 7 days prior), transplant 
related mortality (TRM), relapse, grade II–IV acute GVHD, and chronic GVHD 
(cGVHD).16,17 TRM is defined as death from any cause in the first 28 days post 
transplantation irrespective of relapse status. Death beyond day +28 was only considered 
transplant related if the disease was in remission. TRM was summarized by cumulative 
incidence estimate with relapse as competing risk. Post-HCT relapse was summarized by 
cumulative incidence estimate with TRM as the competing risk. For relapse and TRM, 
patients in continuous complete remission were censored at last follow-up. Donor and 
recipient HLA matching were defined using best available HLA-matching data.18
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Data collection on late effects
Transplant centers reported late effects as part of follow-up CRFs that inquired whether an 
HCT recipient had developed any clinically significant organ impairment or disorder since 
the date of the last report. Specific questions focused on the following late effects: 
neurological (stroke/seizures), cardiovascular (myocardial infarction), gastrointestinal/
hepatic (cirrhosis), genitourinary (gonadal dysfunction/infertility requiring hormone 
replacement, renal failure severe enough to warrant dialysis), musculoskeletal (avascular 
necrosis), special sensory (cataracts), and endocrine (growth hormone deficiency/growth 
disturbance, hypothyroidism) impairment. Responses to each item were dichotomous 
(yes/no) and followed by a question requesting the date of onset for each individual organ 
impairment or disorder. Other late effects were reported using an “other-specify” field that 
was also checked for the late effects of interest.
Statistical Analysis
Variables related to patient, disease, and transplant characteristics were summarized using 
descriptive statistics. Distribution of baseline characteristics among the two age groups 
(children versus young adults) was compared using chi-square test for categorical variables 
and Wilcoxon rank test for continuous variables. The probabilities of OS and LFS were 
calculated using the Kaplan-Meier method. Log-rank p-values were calculated to evaluate 
the overall differences of the Kaplan-Meier estimates. All other outcomes were summarized 
using the cumulative incidence function to take into account the effects of competing risks.19 
Gray’s test p-values were then calculated to evaluate the overall differences across 
cumulative incidence estimates.20 Cox proportional hazards regression was performed for 
multivariate analysis for OS, LFS, relapse, TRM and GVHDs.19 Covariates being tested 
included: patient age, gender, Karnofsky/Lansky performance score at the time of 
transplantation, time from diagnosis to transplantation, TKI use pre-transplant, graft source, 
donor type, total body irradiation (TBI) in conditioning regimen, donor age, donor-recipient 
gender match, recipient cytomegalovirus (CMV) status, GVHD prophylaxis and anti T cell 
therapy used. All covariates were tested for inclusion via stepwise selection. Similarly, 
interactions between the main effect and significant covariates were tested. The proportional 
hazards assumption for each covariate was tested. If violated, the covariate was included as a 
time-dependent variable. When an interaction between the main effect and a covariate was 
found significant, the interaction was adjusted using stratified regression analysis on the 
significant covariate. Logistic regression was used for engraftment. All analyses were 
performed with SAS 9.3 (SAS Institute Inc.). Having a p-value of less than 0.05 was 
considered statistically significant.
Results
We report on 449 young patients with early CML <18 years (n=177) and 18–29 years 
(n=272) transplanted from 2001-10 in CP1 (n=428) and clinical remission (n=28) and 
followed for a median of 6 years (range 0.25–12y) (Table 1). About 50% patients did not 
receive TKIs pre-HCT. Patients received MAC and were equally distributed in the TBI 
versus chemotherapy only conditioning groups. Bone marrow (BM) grafts were more 
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frequently used in pediatrics (p <0.001). Compared to 78% of pediatric patients, only 58% 
of young adults were transplanted within 1 year of diagnosis (p<0.001). Pediatric patients 
tended to be CMV negative and more frequently receive ATG/alemtuzumab compared to 
young adults.
Overall Survival
The probability of overall survival for the whole cohort was 85% (95% CI, 81–88%), 78% 
(95% CI, 74–82%) and 75% (95% CI, 71–79%) at 1, 3 and 5 years after HCT, respectively, 
and was similar among recipients in the pediatric and the young adult group (Supplementary 
data).
Univariate analysis showed 5 year OS was 83% (95% CI, 77–88%) in matched sibling donor 
(MSD) compared to 68% (95% CI, 61–74%) in unrelated donors (URD) (p=<0.001); 80% 
(95% CI, 75–85%) for BM grafts compared to 62% (95% CI, 53–71%) for peripheral blood 
stem cell (PBSC) grafts (p=0.001) (; Figure 1, supplementary data), with no effect of pre-
HCT TKI use (). However on multivariate analysis, only use of unrelated donors (p<0.001) 
and HCTs before 2003 (p=0.04) increased the risk of long-term mortality (Table 2).
Leukemia-Free Survival
Leukemia-free survival rates for the entire cohort at 1, 3 and 5 years post-HCT were 76% 
(95% CI, 72–80%), 63% (95% CI, 58–68%) and 59% (95% CI 54–64%), respectively. On 
univariate analysis, neither age (p=0.63) nor donor type (p=0.11) or graft source (p=0.07) 
affected LFS (Supplementary data; Figure 2). Although pre-HCT TKI use was associated 
with superior LFS (p=0.03) on univariate analysis, this effect was lost on multivariate 
analysis. Only use of ATG/alemtuzumab (p=0.02), PBSC source (p=0.003), and transplant in 
non US centers (p=0.0003) were independent predictors of lower LFS (Table 2).
Engraftment
There was no difference in neutrophil engraftment at day 28 between pediatric patients and 
young adults (p=0.23); however, as expected, more patients receiving peripheral blood as 
graft source engrafted by day 28 (p=0.01) (Table 2). In addition, female patients had a 
significantly increased incidence of neutrophil recovery (p=0.004). Young adult recipients 
had higher incidence of platelet recovery at day 100 (p=0.007) as did recipients of MSD 
grafts (p=0.007).
GVHD
Incidence of grade II–IV aGVHD was 36% (95% CI: 31–40%) and grade 3–4 aGVDH 17% 
(95% CI 13–20%) at 100 days post HCT. Incidence of cGVHD was 46% (95% CI: 42–
51%), 51% (95%CI: 46–56%), and 52% (95% CI: 47–57%) at 1 year, 3 years and 5 years 
post HCT, respectively. Incidence of aGVHD was significantly reduced with bone marrow 
grafts (p<0.001), male donors to male recipients (p=0.01) and ATG/alemtuzumab use 
(p=0.01) but not affected by recipient age (p=0.73). Risk of cGVHD was higher in the young 
adult population (p=0.0002), female donors (p=0.008), PBSC source (p=0.0003), and 
without use of ATG/alemtuzumab (p=0.02) (Table 2). Extensive and limited cGVHD was 
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seen in 21% and 15% of pediatric patients, respectively, as opposed to 41% and 14% of 
young adults, respectively.
Relapse
The cumulative incidence of relapse for the entire cohort was 11% (95% CI 8–14%) at 1 
year, 18% (95% CI 15–22%) at 3 years and 21% (95% CI, 17–25%) at 5 years after HCT. 
As described by reporting centers, relapse (n=104) was hematological, cytogenetic and 
molecular in 41%, 21% and 22%, respectively, with 16% unknown. On multivariate 
analysis, risk of relapse was higher with use of cyclosporine (p=0.03) and alemtuzumab use 
(p<0.001) (Table 2). Relapse rates were unaffected by donor type, graft source, recipient age 
or pre-HCT TKI use (Table 2).
Transplant Related Mortality
The cumulative incidence of TRM for the entire cohort was 13% (95% CI, 10–17%) at 1 
year, 18% (95%CI, 15–22%) at 3 years and 20% (95% CI, 16–24%) at 5 years post HCT. 
Risk of TRM increased with use of unrelated donors (p<0.001), PBSC (p=0.003), CMV 
seropositive recipients (p=0.01) and HCTs prior to 2003 (p=0.02); it was similar in the 
pediatric and young adult patients (p=0.36) (Table 2). Cause of deaths included GVHD 
(n=26), infections (n=12), end organ failure (n=17), idiopathic pneumonitis (n=8), graft 
failure (n=4) and others/unknown (n=17).
Transplant Variables and Outcomes
For the entire cohort of patients <29 years, there was no difference in OS, LFS, relapse or 
TRM with use of pre-HCT TKI therapy, time to HCT from diagnosis, donor age, donor 
recipient ABO mismatch or TBI-based conditioning regimens. The effect of post-HCT TKI 
(used in <15% of all patients for either prophylaxis or treatment) and DLI were not 
evaluated in this data set due to small numbers.
Late Effects
Among 144 pediatric patients with a median follow-up of 6 years, there were 16 cases of 
gonadal dysfunction, 12 avascular necrosis, 8 hypothyroidism, 7 growth deficiency, 6 
diabetes mellitus, 6 new malignancies and 1 cardiac abnormality reported. Among the 201 
young adult patients with similar follow-up, there were 10 cases of gonadal dysfunction, 10 
cataracts, 3 hypothyroidism, 2 diabetes mellitus and 2 with avascular necrosis.
Discussion
Several reports have documented a decline in annual transplantation rates for CML, 
especially among patients in CP1.3,5,8 In the TKI era, HCT is recommended in CP1 patients 
if they are resistant or intolerant to TKI.21,22 Although it is the only established treatment to 
eliminate leukemic stem cells,23 HCT, especially with a myeloablative conditioning 
regimen, causes significant long term morbidities. Children and young adults are known to 
better tolerate HCT, in general, and they typically enjoy superior outcomes compared to 
older adults.12,24,25,26,27 Additionally, advances in supportive care, have led to significant 
reduction in the incidence and impact of HCT-related complications.25,26,27
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Addressing specific prognostic factors for CP-CML and HCT for pediatrics and young 
adults is limited by the relatively small number of patients in single-center reports. 28,29,30 
Given its unique clinical and biological features, CML in the younger age group needs to be 
better categorized.31 The CIBMTR database offers the advantage of a large number of 
patients with extensive data, which permit performance of multivariate analyses. We believe 
our study provides valuable information as data for HCT in children with early CML are 
scarce.
Our study of 449 pediatric and young adult patients with early disease (CP1 or hematologic 
remission) who underwent MAC allogeneic HCT during the past decade (2001–2010) is the 
largest review of young patients in the TKI era. The 5-year OS was 75% for all patients <29 
years, and outcomes were similar in children and young adults although significantly more 
pediatric patients tended to receive pre HCT TKI, BM grafts and HCT within 1 year from 
diagnosis The differences may reflect standard treatment practice differences in the two 
cohorts. Factors contributing to better OS, as expected, include related donors (83%) and 
more recent HCT (2003–2010) due to lower TRM. Although BM donors had a 5-year OS of 
80%, this was not significantly better than PBSC. This finding contrasts with the CIBMTR 
report of a cohort of unrelated donor leukemia patients in which a survival advantage for 
BM in CML-CP1 was described.32 Other reports in similar age group include an EBMT 
registry retrospective analysis that reported a 3-year OS of 75% with a sibling donor and 
65% with a matched unrelated donor (MUD) in children with CP1; and German CML-IV 
study with an OS of 90% when patients were prospectively assigned to HCT for TKI 
intolerance or availability of MSD.33,34 TRM in this young cohort receiving MAC was 
comparable to previous reports and significantly higher in the unrelated donor (p<0.0001), 
PBSC (p=0.001), CMV positive donor (p=0.01) and HCTs before 2003 (p=0.02).30
Five-year LFS for our patient cohort was 59%, and similar to previously described studies; 
worse outcomes were reported with use of unrelated donors and PBSC source. 33,34,35 
Unique to our analysis is the worse LFS seen with use of alemtuzumab but not in the ATG 
group when comparing with those that received none. LFS was significantly worse when 
comparing ATG with alemtuzumab, although the number of patients in this group was small. 
Worse LFS in our patients, especially compared to prospective studies, is likely due to 
heterogeneous patient/donor group in our retrospective analysis however could potentially 
be attributed to NK and additional immune cell depletion with Alemtuzumab that may 
impact GVL.36
Cumulative incidence of relapse at 5 years, 21% for the whole group, is higher than in other 
studies.37,38 This increased relapse may be due to current HCT recommendations that 
potentially select for a group with more aggressive disease than those on prolonged TKIs 
only, who are not traditionally referred for HCT although indications for HCT were not 
captured in CIBMTR database. Relapse was higher in the group receiving ATG/
alemtuzumab and also with the use of cyclosporine over tacrolimus based GVHD 
prophylaxis. The latter finding has not been previously described and needs to be further 
evaluated; and is contrary to reports suggesting decreased graft-versus-leukemia (GVL) 
effect with tacrolimus.39 Alemtuzumab use is often paired with donor lymphocyte infusions 
to decrease risk of relapse, but we were unable to assess for this effect.40 While the curative 
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effect of HCT in CML relies on the graft-versus-leukemia (GVL) effect, similar to other 
reports, donor source/matching did not play a role in decreasing relapse or LFS.41 The role 
of cGVHD in this group needs to be further studied. TBI was surprisingly used in about 35% 
of this young population, equally in both age cohorts although randomized comparison of 
Cy/TBI to BuCy in patients with CML reported comparable OS, LFS and maybe even 
decreased relapse.42,43 Similar to a recent CIBMTR CML study our results showed no 
advantage for TBI.44
We confirmed increased incidence of acute and chronic GVHD with PBSC, female donors 
and regimens without ATG/alemtuzumab. 45,46,47 The protective role of cGVHD in CML 
was recently reported in a CIBMTR analysis confirming earlier studies.48,49,50 Although this 
was not specifically analyzed in our study, there was no difference in relapse/LFS with 
PBSC donors and young adults, both of whom had increased incidence of cGVHD.
Similar to earlier CIBMTR reports, we did not show any impact of pre-HCT TKI use on 
post-HCT outcomes for early CML in young patients.30,48 Given that pre HCT TKI use 
likely interacts with era of HCT leading to change in reported outcomes, adjusted analysis 
was performed to confirm this finding. Imatinib is the only FDA approved TKI in pediatrics. 
The estimated LFS in pediatric patients with early CML treated with imatinib is 98% at 3 
yrs with a complete hematologic response in 98%. 28 However, we would caution that a 
direct comparison between groups receiving HCT to those on TKI alone is flawed as direct 
comparison can be made only if indications for HCT were available. However, in the current 
era, when most patients receive TKI, this finding is less relevant.
Although there are significant differences in graft source, conditioning regimen and donor 
source used by age group (reflecting different practice patterns in pediatric versus young 
adult), there was no difference in clinical outcomes in the pediatric versus young adult age 
group, suggesting that these groups are relatively uniform biologically in terms of age, 
health status and underlying disease.
Late effects in CML HCT were similar to those described with other malignant neoplasms 
HCT survivors. The infrequent occurrence of these events, possibly, in part, due to the 
relatively short follow-up and inconsistent data capture and reporting precludes analysis of 
risk factors such as TBI. As described, gonadal dysfunction and growth failure were 
common whereas very few cardiac adverse events were noted.26 This study was restricted to 
MAC regimens, but several studies have described encouraging long term outcomes with 
RIC conditioning in CML, which is especially relevant in this age group.51,52,53 With 
increasing number of reports of side effects of TKI, such as growth abnormalities, cardiac 
events and infertility in this group of patients, it is important to better describe long-term 
effects of HCT to establish guidelines for treatment.54,55,56,57,58,59
We recognize the limitations of these analyses. Some outcomes of interest were unavailable, 
such as the indications for HCT in early CML (planned versus resistance to TKI/donor 
availability); molecular/cytogenetic disease status at the time of HCT and relapse; and BCR/
ABL1 mutations. The retrospective study design also limited our ability to report 
comprehensively on late effects. While the best way to determine the benefit of HCT for 
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children and young adults with early CML is to conduct a prospective randomized trial 
comparing upfront HCT and TKI therapy, it is unlikely to have sufficient number of patients 
for such a study.
In conclusion, children and young adults with early CML have similar outcomes with HCT. 
When indicated, HLA MSD and BM stem cell source lead to best outcomes with no benefit 
for radiation containing regimens. There is a need for prospective trials in this age group to 
better define guidelines for HCT, improving post HCT relapse rates without need for 
lifelong dependence on TKI.
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Refer to Web version on PubMed Central for supplementary material.
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- Outcomes for hematopoietic stem cell transplant are similar in pediatric and 
young adult patients
- OS and LFS superior with matched sibling donors and bone marrow as stem 
cell source
- Pre HCT tyrosine kinase use did not alter outcomes in for hematopoietic stem 
cell transplant in pediatric and young adult patients
- No role for irradiation in myeloablative conditioning regimen pre HCT
- Role of hematopoietic stem cell transplant in pediatric and young adults in 
early CML needs to be better defined
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Overall Survival in CML patients (n=449) transplanted in early disease (CP1, hematological 
remission) by donor type
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Leukemia Free Survival in CML patients (n=449) transplanted in early disease (CP1, 
hematological remission) by donor type
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Table 1
Characteristics of pediatric and young adult patients (0–29 years) undergoing allogeneic Hematopoietic Cell 
Transplantation (HCT) for early CML between 2001 and 2010, grouped by age





Number of patients 177 272
    CP-1 164(93) 257
    Clinical remission 13(7) 15(6)
Number of centers 80 102
Age at transplant, median 14 (1–18) 24 (18–29) <0.001
Gender 0.18
    Male 101 (57) 173 (63)
Pre HCT Karnofsky/Lansky score 0.43
    90–100% 150 (85) 235 (86)
Country 0.02
    US 101 (57) 126 (46)
    Other countries 76 (43) 146 (54)
TKI pre HCT 0.04
    No TKI 70 (40) 141 (52)
    TKI + 107 (60) 131 (48)
Graft type <0.001
    Bone marrow 138 (78) 156 (57)
    Peripheral blood stem cell 39 (22) 116 (43)
Type of donor 0.24
    HLA Matched sibling donor 82 (46) 142 (52)
    HLA matched unrelated donor 57 (32) 89 (33)
    HLA Mismatched unrelated donor 38 (22) 41 (15)
Conditioning regimen 0.77
    Total Body Irradiation based 62 (35) 92 (34)
    Busulfan based 115 (65) 177 (65)
    Other 0 3 (1)
Year of transplant 0.008
    2001–2002 32(18) 84(31)
    2003–2004 63(36) 83(31
    2005–2006 50 (28) 79 (29)
    2007–2008 17(10) 16(6)
    2009–2010 15(8) 10(4))
Median unrelated donor age (years)
(range)
34 (19–59) 33 (19–54) 0.51
Time from diagnosis to HCT <0.001
    0–6 months 49 (28) 65 (24)
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    6–12 months 88 (50) 92 (34)
    >= 12 months 40 (23) 115 (42)
Donor-recipient sex match 0.10
    M-M 57 (32) 112 (41)
    M-F 45 (25) 46 (17)
    F-M 44 (25) 61 (22)
    F-F 31 (18) 53 (19)
Recipient CMV status <0.001
    Negative 109 (62) 113 (41)
    Positive 66 (37) 154 (57)
    Unknown 2 (1) 5 (2)
Donor-recipient ABO match 0.86
    Matched 94 (53) 152 (56)
    Minor mismatch 24 (14) 40 (15)
    Major mismatch 34 (19) 51 (19)
    Bi-directional 11 (6) 13 (5)
        Unknown 14 (8) 16 (6)
GVHD prophylaxis 0.14
    FK506 based 43 (24) 84 (31)
    CSA based 134 (76) 188 (69)
Serotherapy used <0.001
    ATG 43 (24) 37 (14)
    Alemtuzumab 14 (8) 8 (3)
    No ATG or Alemtuzumab 120 (68) 228 (84)
Post-HCT donor lymphocyte infusion 0.45
    No 161 (91) 250 (92)
    Yes 15 (8) 22 (8)
    Unknown 1 (<1) 0
Post-HCT TKI (planned pre HCT) 0.01
    No 160 (90) 259 (95)
    Yes 16 (9) 8 (3)
    Missing 1 (<1) 5 (2)
Post-HCT TKI (not planned pre HCT) 0.58
    No 154 (87) 239 (88)
    Yes 22 (12) 29 (11)
    Missing 1 (<1) 4 (1)
Median follow-up of survivors (range),
months
72 (3–146) 72 (3–148)
TKI: tyrosine kinase inhibitors, ATG: Antithymocyte globulin, CP-1-Chronic phase 1
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